يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Clemens H M Mellink"', وقت الاستعلام: 0.39s تنقيح النتائج
  1. 1

    المساهمون: Immunology, Hematology, Human Genetics, ARD - Amsterdam Reproduction and Development, ACS - Pulmonary hypertension & thrombosis, ANS - Complex Trait Genetics, CCA - Cancer biology and immunology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life

    المصدر: Leukemia, 36(7), 1935-1938. Nature Publishing Group
    Hengeveld, P J, Ertem, Y E, Dubois, J M N, Mellink, C H M, van der Kevie-Kersemaekers, A-M, Evers, L M, Heezen, K, Kolijn, P M, Mook, O R F, Motazacker, M M, Nasserinejad, K, Kersting, S, Westerweel, P E, Niemann, C U, Kater, A P, Langerak, A W & Levin, M-D 2022, ' Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110 ', Leukemia, vol. 36, no. 7, pp. 1935-1938 . https://doi.org/10.1038/s41375-022-01600-6

    وصف الملف: application/pdf

  2. 2

    المساهمون: Hematology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Human Genetics, ARD - Amsterdam Reproduction and Development

    المصدر: The Lancet Oncology, 23(6), 818-828. Lancet Publishing Group
    Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
    Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
    The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Group

    وصف الملف: application/pdf

  3. 3